This company is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Humanigen Dividendo
Dividendo criteri di controllo 0/6
Humanigen does not have a record of paying a dividend.
Informazioni chiave
n/a
Rendimento del dividendo
n/a
Rapporto di remunerazione
| Rendimento medio del settore | 1.9% |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | n/a |
| Utile per azione | -US$0.45 |
| Previsione del rendimento del dividendo | 0% |
Aggiornamenti recenti sui dividendi
Nessun aggiornamento
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04
Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Insufficient data to determine if HGEN.Q's dividends per share have been stable in the past.
Dividendo in crescita: Insufficient data to determine if HGEN.Q's dividend payments have been increasing.
Rendimento dei dividendi rispetto al mercato
| Humanigen Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (HGEN.Q) | n/a |
| Fondo del 25% del mercato (US) | 1.4% |
| Top 25% del mercato (US) | 4.3% |
| Media del settore (Biotechs) | 1.9% |
| Analista previsionale (HGEN.Q) (fino a 3 anni) | 0% |
Dividendo notevole: Unable to evaluate HGEN.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividendo elevato: Unable to evaluate HGEN.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Distribuzione degli utili agli azionisti
Copertura degli utili: Insufficient data to calculate HGEN.Q's payout ratio to determine if its dividend payments are covered by earnings.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Unable to calculate sustainability of dividends as HGEN.Q has not reported any payouts.